- AstraZeneca said its type-2 diabetes drug on top of standard care showed a reduction in both the incidence of cardiovascular death and the worsening of heart failure in patients with and without type-2 diabetes.

The trial of Farxiga (dapagliflozin) on top of standard of care showed a 30% decrease in the risk of experiencing a first episode of worsening heart failure and an 18% decrease in the risk of dying from cardiovascular causes, the company said.

The trial results also showed a significant improvement in patient reported outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score and a nominally significant reduction in all-cause mortality by 17% (7.9 versus 9.5 patients with an event per 100 patient-years) in favour of Farxiga.

'Farxiga is well established in the treatment of type-2 diabetes, and these exciting new findings offer clinically meaningful insights into the potential of the medicine to reduce the burden of heart failure in patients with and without type-2 diabetes. We are proud to be contributing to the scientific body of evidence during the ESC Congress 2019,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.

The update comes after the topline results announced last month showed DAPA-HF had met the primary endpoint.

Story provided by